Sanofi's oncology R&D group marks a pair of setbacks on isatuximab/Libtayo combo as cancer studies fizzle out
Sanofi’s cancer R&D group has suffered a setback with the failure of a pair of clinical trials matching their CD38 contender isatuximab with Regeneron’s PD-1 checkpoint Libtayo (cemiplimab) for non-small cell lung as well as prostate cancers.
All we know from the pharma giant is contained in a brief mention of the burial in their Q3 report out Thursday, noting that the combination studies were iced after investigators found that they had fizzled on the efficacy side. Safety was not an issue.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,800+ biopharma pros reading Endpoints daily — and it's free.